U.S. probes deaths of patients using pain patches
Posted on: Friday, 15 July 2005, 14:07 CDT
WASHINGTON (Reuters) - U.S. regulators are investigating reports of deaths of patients who were using pain patches that contain the narcotic fentanyl, the Food and Drug Administration said on Friday.
Johnson & Johnson sells fentanyl patches under the brand name Duragesic, and Mylan Laboratories Inc. markets a generic version. Johnson & Johnson told doctors in June it was adding warnings to the Duragesic label about the potential for abuse and misuse of the product.
The FDA said in a statement it was "conducting an investigation into the deaths associated with these patches."
"The agency has been examining the circumstances of product use to determine if the reported adverse events may be related to inappropriate use of the patch or factors related to the quality of the product," the FDA said.
The FDA advised patients to follow directions on how to use the patch properly to avoid an overdose.
Officials at Johnson & Johnson and Mylan did not immediately return calls seeking comment.
Source: REUTERS
Related Articles
- LifeNet Health and Children's Mercy Hospital Announce First Implant With MatrACELL(TM) Technology
- CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
- American Dental Hygienists' Association and Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. Announce Honorees of HYGIENIST HERO(R) Recognition Program
- OMRIX Biopharmaceuticals Initiates Phase II Clinical Trial for Fibrin Patch Product Candidate
- Noven Provides Update on Daytrana(TM) Methylphenidate Transdermal System
- CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients With Metastatic Breast Cancer
- Caring Today Magazine Supports Johnson & Johnson's Caregiver Initiative
- COLUMN: Wal-Mart Cares About Finances, Not Morals
- FDA Warning on Nicotine Patches Cleared
- Roseville, Minn.-Based Software Firm Buys Supplier for Non-Windows Systems
 |
 |
User Comments (0)
RSS Feeds